- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 7 - The Complexities of Pathway Development
Dr Sonnad inquired how replacing brand drugs with generic equivalents can affect pathway adherence. She also asked panelist to discuss the differences between early-stage and late-stage disease regimens, as well as the degree of flexibility there is in regimen design.
Dr Sonnad inquired how replacing brand drugs with generic equivalents can affect pathway adherence. She also asked panelists to discuss the differences between early-stage and late-stage disease regimens, as well as the degree of flexibility there is in regimen design.
Dr Nabhan said providers’ participation in pathway development is essential. They are likely to offer a variety of critical contributions and recommendations, including the ability to recognize the nuances between early-stage and late-stage disease states.
Dr Yu said that documentation is not only key to regimen flexibility, but to monitor pathway toxicity. Developing regimens can also vary, more greatly for late-stage disease than it does for early-stage disease.
Dr Tischler said this disease state variation also means that regimens can be flexible. As a disease becomes more complex, however, it may be difficult to offer generic medications.
Dr Nabhan said pathways may need to adapt to newer medications, but there needs to be data to support their effectiveness so that they can be be included in a regimen.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Reducing Low-Value Care Is Hard, but What About Just Not Paying for It?
March 14th 2024After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.
Read More
